Why ImmunityBio, Inc. (IBRX) stock moved
ImmunityBio, Inc. (IBRX) shares tumbled 7.3% to $8.22 as of July 11, 2026, a significant decline from the prior close of $8.87. BestStocks flagged the session as a major change for IBRX. Below, we break down what changed for IBRX, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
IBRX fell 7.3% to $8.22
IBRX tumbled 7.3% in its latest session, moving from $8.87 to $8.22.
What it means for ImmunityBio, Inc. investors
For ImmunityBio, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: ImmunityBio, Inc. (IBRX) moved +2.61% from $9.20 to $9.44 on 2026-07-02.; Positive price momentum. Weighing against that: Sharp 7.3% decline — elevated risk; ImmunityBio fell 8.23% to $8.14 as part of a broader biotech sector selloff on Friday, July 10.. Wall Street's consensus price target sits at $13.00, implying +58.2% upside from $8.22. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 24 days out, the next report is the most likely near-term test of the move.
IBRX price reaction
IBRX last traded at $8.22, down $0.65 (-7.33%) from the previous close of $8.87. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $6.72 and $9.44, and it currently sits about 55% of the way up that band.
Bullish and bearish analyst opinions on ImmunityBio, Inc. (IBRX)
The consensus analyst price target on ImmunityBio, Inc. (IBRX) is $13.00, 58.2% above the recent $8.22. Over the past 90 days analysts logged 0 upgrades, 5 maintains, and 0 downgrades. Here is how the bullish and bearish cases on IBRX line up.
The bullish case
- Wall Street's consensus price target of $13.00 implies +58.2% upside from $8.22.
- The Street's most bullish target is $15.00 (+82.5%).
- ImmunityBio, Inc. (IBRX) moved +2.61% from $9.20 to $9.44 on 2026-07-02.
- Positive price momentum.
The bearish case
- Sharp 7.3% decline — elevated risk.
- ImmunityBio fell 8.23% to $8.14 as part of a broader biotech sector selloff on Friday, July 10.
- ImmunityBio (IBRX) fell 9.60% to $8.53 intraday, according to FMP delayed data.
- IBRX moved -5.61% from $9.44 to $8.91 on 2026-07-06.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 11, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for IBRX
Frequently asked questions about IBRX
Why did ImmunityBio, Inc. (IBRX) stock move?
IBRX tumbled 7.3% to $8.22. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did IBRX stock fall?
IBRX lost 7.33% ($0.65) versus the prior close of $8.87, last trading at $8.22 on 0.9× average volume.
When is ImmunityBio, Inc.'s next earnings date?
IBRX's next earnings report is estimated for 2026-08-04 — about 24 days away.
What is the analyst price target for IBRX?
The consensus analyst price target for IBRX is $13.00, about 58.2% above the current $8.22. Over the past 90 days, analysts recorded 0 upgrades, 5 maintains, and 0 downgrades.
How BestStocks tracks IBRX
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared IBRX-specific materiality thresholds, triggering an evidence check. It draws on 7 tracked change events for IBRX, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 11, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.